关键信息
-
基因名
ACP5
- 应用
-
别名
TRAP; TrATPase; Tartrate Resistant Acid Phosphatase; Type 5 acid phosphatase
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q05117
-
表达区间
Leu28~Gly286
-
分子量
30kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
ACP5, also known as Acidic Calcium Phosphate Phosphatase 5, is a key enzyme involved in bone mineralization and phosphate metabolism. Its primary role is to hydrolyze inorganic pyrophosphate (PPi) to inorganic phosphate (Pi), which is essential for the proper mineralization of bone and teeth. Dysregulation of ACP5 activity can lead to pathological conditions such as osteomalacia and deficiencies in bone density, highlighting its significance in skeletal health. Recent studies have focused on the structure-function relationship of ACP5, utilizing recombinant protein techniques to produce and characterize the enzyme in vitro. This allows researchers to explore its catalytic mechanisms and regulatory pathways, providing insights into its role in bone physiology and potential therapeutic targets for bone-related diseases. Furthermore, understanding ACP5's interaction with other biomolecules and its regulation by post-translational modifications is crucial for elucidating its broader implications in metabolic disorders. The development of specific inhibitors or enhancers of ACP5 could pave the way for novel strategies in treating conditions associated with abnormal phosphate metabolism, illustrating the need for continued research in this area.
